Robert Marcus
Stock Analyst at JP Morgan
(1.49)
# 3,517
Out of 5,129 analysts
24
Total ratings
55.56%
Success rate
-0.26%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Robert Marcus
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| BDX Becton, Dickinson and Company | Maintains: Neutral | $190 → $175 | $180.62 | -3.11% | 11 | Feb 10, 2026 | |
| PEN Penumbra | Upgrades: Overweight | $275 → $370 | $338.26 | +9.38% | 5 | Dec 18, 2025 | |
| IART Integra LifeSciences Holdings | Upgrades: Neutral | $75 | $11.18 | +570.84% | 2 | Dec 17, 2021 | |
| GKOS Glaukos | Downgrades: Underweight | $50 | $109.03 | -54.14% | 2 | Oct 8, 2020 | |
| TMDX TransMedics Group | Downgrades: Neutral | $15 | $133.30 | -88.75% | 2 | Oct 8, 2020 | |
| ATRC AtriCure | Maintains: Overweight | $48 → $57 | $32.95 | +72.99% | 2 | Jul 29, 2020 |
Becton, Dickinson and Company
Feb 10, 2026
Maintains: Neutral
Price Target: $190 → $175
Current: $180.62
Upside: -3.11%
Penumbra
Dec 18, 2025
Upgrades: Overweight
Price Target: $275 → $370
Current: $338.26
Upside: +9.38%
Integra LifeSciences Holdings
Dec 17, 2021
Upgrades: Neutral
Price Target: $75
Current: $11.18
Upside: +570.84%
Glaukos
Oct 8, 2020
Downgrades: Underweight
Price Target: $50
Current: $109.03
Upside: -54.14%
TransMedics Group
Oct 8, 2020
Downgrades: Neutral
Price Target: $15
Current: $133.30
Upside: -88.75%
AtriCure
Jul 29, 2020
Maintains: Overweight
Price Target: $48 → $57
Current: $32.95
Upside: +72.99%